Overview
Neurolentech develops patient-derived neuronal cell models from iPSCs for drug discovery and diagnostics targeting neurodevelopmental disorders like autism, epilepsy, and intellectual disability. Their precision medicine platform combines disorder-specific models with molecular and physiological assays to identify druggable targets and validate therapeutics. They partner with biopharma companies to advance treatments for these high-unmet-need conditions.
Frequently asked questions
- What capabilities does Neurolentech offer for neurodevelopmental disorder drug discovery?
- Neurolentech provides a platform with proprietary patient-derived iPSC neuronal cell models and functional assays for epilepsy, autism, and related NDDs to identify molecular mechanisms and validate therapeutics.
- What types of cell models and assays are available?
- They offer human iPSC-derived neuronal models from patients across the NDD spectrum, with assays interrogating molecular and cellular disease mechanisms.
- Who are Neurolentech's typical partners and geographies?
- Neurolentech partners with biopharma like Kaerus Bioscience and o2h technology; as an IST Austria spin-out based in Austria, they serve global pharma clients focused on NDD research.